These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22616398)

  • 21. Competing for public funding of medicines to treat rare disorders in New Zealand.
    Crausaz S
    Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
    [No Abstract]   [Full Text] [Related]  

  • 22. Expensive health care. A solvable problem?
    Oswalt CE
    Arch Intern Med; 1990 Jun; 150(6):1165-6. PubMed ID: 2353851
    [No Abstract]   [Full Text] [Related]  

  • 23. Obligations and marginal decisions in a fair health system.
    Berger JT
    Am J Bioeth; 2004; 4(3):123-4; discussion W40-2. PubMed ID: 16192171
    [No Abstract]   [Full Text] [Related]  

  • 24. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 25. Rare diseases and effective treatments: are we delivering?
    Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
    Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
    [No Abstract]   [Full Text] [Related]  

  • 26. Social ethics and organizational structures influencing the allocation of health care in Germany and the United States.
    Miller AE
    J Contemp Health Law Policy; 2002; 18(3):649-61. PubMed ID: 12491661
    [No Abstract]   [Full Text] [Related]  

  • 27. Shifting the focus of rationing discussions.
    Stark M
    Am J Bioeth; 2011 Jul; 11(7):20-2. PubMed ID: 21745076
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis.
    Rai AK
    Soc Philos Policy; 2002; 19(2):246-70. PubMed ID: 12678089
    [No Abstract]   [Full Text] [Related]  

  • 29. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
    J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 33. Medicare coverage for technological innovations.
    Wynia MK; Witlen R
    N Engl J Med; 2004 Aug; 351(7):719-20; author reply 719-20. PubMed ID: 15306678
    [No Abstract]   [Full Text] [Related]  

  • 34. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access.
    Copley-Merriman K
    Value Health; 2018 May; 21(5):491-492. PubMed ID: 29753343
    [No Abstract]   [Full Text] [Related]  

  • 35. Limits on use of health economic assessments for rare diseases.
    Hyry HI; Stern AD; Cox TM; Roos JC
    QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Towards more targeted therapies in a contraint economy].
    Toumi M
    Med Sci (Paris); 2018 May; 34 Hors série n°1():45-47. PubMed ID: 29911562
    [No Abstract]   [Full Text] [Related]  

  • 37. Ethical dilemmas about orphan drugs for orphan diseases.
    Isaacs D
    J Paediatr Child Health; 2014 Apr; 50(4):249-50. PubMed ID: 24698059
    [No Abstract]   [Full Text] [Related]  

  • 38. Response.
    McPherson J
    J Bioeth Inq; 2005; 2(2):114-5. PubMed ID: 16317874
    [No Abstract]   [Full Text] [Related]  

  • 39. The balancing act of orphan drug pricing.
    The Lancet
    Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA program could boost treatments for neglected diseases.
    Traynor K
    Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.